Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland

ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effe...

Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )

Glofitamab induces durable complete remissions in patients with relapsed large B...

Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma ( Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia )

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in ...

Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )

A novel CAR-T cell therapy targeting BCMA is highly effective for patients with ...

Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain

$A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )$

A single dose of ctx001 shows promising efficacy and safety for TDT and severe S...

Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy

A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD ( Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker ca...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...

Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for youn...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...

Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford

ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )

More from ecancer